IndustryCompany release

Gilead raises 2026 sales guidance after 13% rise in third-quarter product sales

🇺🇸 Gilead Sciences, Inc. (GILD) · Thu 29 Oct 2026

Gilead reports Q3 product sales of $8.3bn, driven by HIV growth, and lifts full-year guidance while noting a new FDA approval and wider voluntary licensing for lenacapavir.

Gilead Sciences reported third-quarter 2026 results on 29 October, with product sales up 13% to $8.3bn. The company raised its full-year product sales guidance to $31.0bn-$31.3bn.

HIV was the main driver, with sales up 18%. Gilead attributed the growth to Biktarvy, Descovy and demand for HIV prevention. Trodelvy and Livdelzi also grew over the period.

Not all products moved in the same direction. Sales of Veklury and of cell therapy products declined in the quarter.

Gilead also noted that the US Food and Drug Administration has approved Bixlenvo, a single-tablet HIV regimen combining bictegravir and lenacapavir.

On access, the company said it has expanded its royalty-free voluntary licensing to cover investigational once-yearly lenacapavir for HIV prevention. Voluntary licences generally allow approved generic manufacturers to produce a medicine for supply in specified lower-income markets.

What it means for your team

  • Market-access teams should note the 18% HIV growth, which Gilead links partly to prevention demand, as a sign of where the portfolio is concentrated.
  • Regulatory teams can track Bixlenvo as a newly FDA-approved single-tablet bictegravir/lenacapavir regimen.
  • Once-yearly lenacapavir for HIV prevention remains investigational, yet it is already covered by Gilead's royalty-free voluntary licensing, which is relevant to access planning in licensed markets.
  • Declines in Veklury and cell therapy sales show that growth across the portfolio is uneven.

Company's press release (SEC filing): Gilead Sciences, Inc. ↗

Article written by VigiEye from the official source (Gilead Sciences, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →